TABLE 2.
Overview of availability of originator adalimumab and biosimilars in the different European countries surveyed (as of May 10, 2019).
| Country | Originator adalimumab | Amgevita® | Hulio® | Hyrimoz®/Hefiya®/Halimatoz® | Imraldi® | Idacio®/Kromeya® | Other |
|---|---|---|---|---|---|---|---|
| Albania | X | — | X | — | — | — | — |
| Austria | X | X | X | X (Hyrimoz®) | X | — | — |
| Belgium | X | X | X | X (Hyrimoz®) | X | — | — |
| Bulgaria | X | X | X | X (Hyrimoz®) | — | — | — |
| Croatia | X | X | X | X (Hyrimoz®) | X | — | — |
| Cyprus | X | — | — | — | — | — | — |
| Czech rep | X | X | X | X (Hyrimoz®) | X | — | — |
| Denmark | X | X | - a | X (Hyrimoz®) | X | — | — |
| Estonia | X | — | X | — | X | — | — |
| Finland | X | X | X | X (Hyrimoz®) | — | — | — |
| Germany | X | X | X | X (Hyrimoz®) | X | X (Idacio®) | — |
| Greece | X | - (Not yet reimbursed)° | - (Not yet reimbursed)° | - (Not yet reimbursed)° | - (Not yet reimbursed)° | -° | — |
| Iceland | X | — | — | — | X | — | — |
| Ireland | X | X | X | — | X | — | — |
| Italy | X | X | — | X (Hyrimoz®) | X | — | — |
| Kosovo | — | — | — | — | — | — | — |
| Latvia | X | — | — | X (Hyrimoz®) | — | — | — |
| Lithuania | X | X | X | — | — | — | — |
| Malta | X | — | — | — | — | — | — |
| Netherlands | X | X | X | X (Hyrimoz®) | X | — | — |
| Norway | X | X | X | X (Hyrimoz®) | X | — | — |
| Poland | X | X | — | X (Hyrimoz®) | X | — | — |
| Romania | X | X | X | X (Hyrimoz®) | — | — | — |
| Russia | X | — | — | — | — | — | X (Dalibra®) |
| Scotland | X | X | X | X (Hyrimoz®) | X | — | — |
| Serbia | X | — | — | — | — | — | — |
| Slovenia | X | X | X | X (Hyrimoz®) | X | — | — |
| Spain | X | X | X | X (Hyrimoz®) | X | — | — |
| Srpska | X | — | — | — | — | — | — |
| Sweden | X | X | X | X (Hyrimoz®) | X | — | — |
X: Available (i.e. patient access via reimbursement/funding).
-: Not available to patients.
a
Product might be on the market and reimbursed, but not first-choice in the recommended ranking.
°: Reimbursed since July 2020.